The bone marrow niche is recognized as a central player in maintaining and regulating the behavior of hematopoietic stem and progenitor cells. Specific gain-of and loss-of function experiments perturbing a range of osteolineage cells or their secreted proteins had been shown to affect stem cell maintenance (Calvi et [6, 7] ). We used specific in vivo cell deletion approaches to dissect the niche cell-parenchymal cell dependency in a complex bone marrow microenvironment. Endogenous deletion of osteocalcin-expressing (Ocn + ) cells led to a loss of T immune cells (Yu et al., 2015 [8] . 
Experimental design, materials and methods

Mouse models
Eight to twelve-week-old mice were used for all the experiments unless otherwise specified. Mice carrying a fusion of Cre recombinase with a modified estrogen receptor (ERt) under the control of the murine Osterix promoter (Osx-CreERt2 [9] ), hereafter called OsxCre, were crossed with mice bearing a Rosa26-loxP-stop-loxP-mcherry (RosamCh) transgene (OsxCre;Rosa-mCh). Administration of the estrogen analog, 4-hydroxy-tamoxifen (4-OHT) to OsxCre 
Flow cytometry
For each mouse, tibiae, femurs, iliac crests, spines, ulnae, radii, and humeri were collected for bone marrow cells. Muscles and soft tissue were thoroughly removed from the bones that were flushed to remove the bone marrow content. Bone fragments were cut into small fragments and transferred into a pre-warmed collagenase solution (Stemcell Technologies), for 1 h at 37°with vigorous shaking. The solution was then filtered through a 40 μm filter and the flow-through was pelleted and further processed for FACS sorting or RNA extraction.
RNA isolation
Cells were sorted in 750 μl of TRIzol® (Invitrogen) and RNA was extracted according to the instructions of the manufacturer.
Microarrays
Osx + , ++ and Ocn + cells were sorted at 6 days post tamoxifen injection from 4 to 6 weeks adults by using the FACSAria. RNA was extracted using the TRIzol® (Invitrogen) according to the manufacturer's instructions. Samples were further processed by the NuGen Ovation V2 laboratory Process in the microarray core facility of Dana-Farber Cancer Institute. Briefly, first stand cDNA was prepared from total RNA using a DNA/RNA chimeric primer and a reverse transcriptase. The resulting double stranded cDNA with a unique heteroduplex at the 5' end of the antisense strand was amplified using SPIATM amplification, a repeated process of SPIATM DNA/RNA primer hybridization, DNA replication, strand displacement and RNA cleavage which resulted in a rapid accumulation of cDNA with sequence complementary to the original RNA. The SPIATM amplified cDNA was purified using the Zymo Research DNA Clean & ConcentratorTM system. The purified cDNA was fragmented through a chemical and enzymatic process and labeled via enzymatic attachment of a biotin-labeled nucleotide to the 3′-hydroxyl end of the fragmented cDNA. The biotinylated cDNA was added to a hybridization solution containing several biotinylated control oligonucleotides (for quality control), and hybridized to the Mouse430A microarray chip overnight at 45°C. The chips were then transferred to a fluidics instrument that performs washes to remove cDNA that has not hybridized to its complementary oligonucleotide probe. The bound cDNA was then fluorescently labeled using phycoerythrin-conjugated streptavidin (SAPE); additional fluors were then added using biotinylated antistreptavidin antibody and additional SAPE. Each cDNA bound at its complementary oligonucleotide was excited using a confocal laser scanner, and the positions and intensities of the fluorescent emissions were captured. These measures provide the basis of subsequent biostatistical analysis. Standard QA/QC analyses involved chip analysis with the assayQualityMetrics BioConductor package and found no significant quality issues with any of the chips, as determined by (among other methods) visual inspection, intensity distributions or RNA degradation plots.
Quality assessment
Standard QA/QC analyses involved chip analysis with the assayQualityMetrics BioConductor package and found no significant quality issues with any of the chips, as determined by (among other methods) visual inspection, intensity distributions or RNA degradation plots. The data was background corrected and normalized with RMA (Robust Multichip Average) using the "affy" BioConductor package. Values in the data matrix represent log2 normalized intensity values.
Differential expression quantification and classification
Supervised learning or class prediction methods were used for molecular classification and pattern recognition. This analysis involves selecting the features (genes) most correlated with a phenotypic distinction of interest. These features or "marker genes" are biologically interesting in themselves but they can also be used as the input of a classification algorithm that uses existing "labeled" samples to build a model to predict the labels for future samples. Genes correlated with a binary class distinction, for example a morphological or clinical phenotype, is directly identified and selected by using a "distance" metric, for example t-test statistic = (mA 
